Malvern, PA, June 1, 2015 – PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing treatments for metabolic and specialty cardiopulmonary disorders, announced today that data on its compounds PE0139, a super-long-acting basal insulin, and PB1023, a weekly GLP-1 receptor agonist, have been accepted for two oral presentations at the American Diabetes Association 75th Scientific Sessions (ADA) to be held June 5-9 at the Boston Convention and Exhibition Center in Boston, MA.

Details of the oral presentations are as follows:

Title: PE0139, the First Recombinant Fully Human Monomeric Super-Long-Acting Basal Insulin to Display a Sustained Nearly Peakless Insulin Profile following a Single Subcutaneous Dose in Subjects with T2DM Supporting Weekly Dosing

Session: Basal Insulin Analogs—New Evidence

Date: Saturday, June 6

Time: 3:30 – 3:45 p.m.

Location: Room 210

Presentation number: 100-OR

Presenting author: Poul Strange, MD, Ph.D., PhaseBio Pharmaceuticals, Inc.


Title: Synergistic Action of PE0139, a Super-Long-Acting Basal Insulin, and PB1023 a Weekly GLP-1 Receptor Agonist

Session: Combining Basal Insulin and GLP-1 Agonists

Date: Sunday, June 7

Time: 8:30 – 8:45 a.m.

Location: Room 210

Presentation number: 168-OR

Presenting author: Jim Ballance, Ph.D., PhaseBio Pharmaceuticals, Inc.

 

Abstracts for each presentation and additional information on the meeting can be found on the ADA web site: http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=95010.

 


 

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company’s proprietary discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are tuned for a specific rate of absorption, thereby increasing efficacy and reducing side effects. The Company’s lead development candidates are PE0139, a novel super-long-acting basal insulin-ELP fusion for weekly dosing; and PB1046, a weekly VIP receptor agonist for treatment of acute and chronic heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA.